Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib

Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Hongping, Lee, Kee Wah, Chen, Jianxiang, Kong, Shik Nie, Sekar, Karthik, Deivasigamani, Amudha, Seshachalam, Veerabrahma Pratap, Goh, Brian Kim Poh, Ooi, London Lucien, Hui, Kam M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592242/
https://www.ncbi.nlm.nih.gov/pubmed/28900541
http://dx.doi.org/10.1038/cddiscovery.2017.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592242/
https://www.ncbi.nlm.nih.gov/pubmed/28900541
http://dx.doi.org/10.1038/cddiscovery.2017.58

Ejemplares similares